--- title: 'Director, Strategic Finance at BridgeBio Pharma' canonical: 'https://feeny.ai/job/director-strategic-finance-bridgebio-pharma-palo-alto-ednwrg4rpcwx' type: 'job' last_seen: '2026-11-04' --- # Director, Strategic Finance at BridgeBio Pharma - **Company:** BridgeBio Pharma - **Location:** Palo Alto, CA - **Compensation:** $237k–$275k - **Posted:** 2026-05-26 - **Last confirmed live:** 2026-11-04 - **Apply:** https://job-boards.greenhouse.io/bridgebio/jobs/5144756007 ## Job description Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work. ## What You'll Do BridgeBio is seeking a highly motivated and experienced individual to join as an Associate Director or Director of Strategic Finance. The role reports to Strategic Finance and Investor Relations and will be instrumental in driving the company’s corporate finance and capital markets efforts to support growth and enhance shareholder value. The position is designed for an individual who can operate at the intersection of science, strategy, and finance, and translate complex analyses into clear recommendations for executive leadership and the Board. This role is focused on evaluating and executing strategic and financial opportunities at BridgeBio. A successful candidate will demonstrate exceptional problem-solving ability, strong independent judgment, and the capacity to translate complex scientific and financial analyses into clear, decisive recommendations for executive leadership. We are looking for a hardworking and collaborative candidate that can thrive in a fast-paced environment with strong attention to detail. ## Responsibilities - Transaction Leadership: Lead end-to-end evaluation and execution of strategic transactions, including licensing, M&A, structured financings, and asset-level partnerships—from opportunity framing through diligence, valuation, and negotiation support. - Capital Allocation & Strategic Analysis: Partner with senior leadership to evaluate key business and financial decisions through insights, scenario modeling, and assessment of strategic options. - Decision Modeling & Valuation: Apply advanced valuation frameworks (e.g., real options, probabilistic modeling) to inform investment decisions and transaction structuring. - Executive & Investor Communication: Synthesize complex analyses into clear recommendations for senior leadership, the Board, and external stakeholders, including materials supporting capital markets activity and strategic transactions. - Investor Relations & Consensus Management: Support investor relations activities through analysis of Street models, management of external expectations, development of investor materials, and preparation for earnings and key corporate events. Where You'll Work This is an in-person role and requires in-office collaboration 4-5 days per week, primarily in our Palo Alto office. ## Who You Are Qualities - Mission-oriented: Motivated by the opportunity to help advance life-saving medicines. - Curious and hardworking: Thoughtful, diligent, committed to delivering high-quality work. - Focused on results: Willing to take ownership and see projects through to completion. - Multitasker: Comfortable working across several high-stakes workstreams. - Self-motivated: Thrives in a dynamic, fast-paced environment. - Team-oriented: Values collaboration and supports others across the organization. ## Experience - Bachelor’s degree in science, engineering, business, finance, economics, or a related analytical discipline required - Advanced scientific or clinical degree, including PhD, MD, PharmD, or equivalent experience, strongly preferred - 4-7 years of experience in management consulting, investment banking, or biotech corporate finance / strategic finance, with demonstrated progression to leading teams or workstreams (e.g., Engagement Manager, Vice President, or equivalent) ## Skills - Exceptional problem-solving skills with a first-principles approach to complex scientific and business questions - Independent thinker who forms and defends a view, including a non-consensus one, rather than summarizing others’ work - Resourceful researcher who goes to primary sources (filings, transcripts, letters, precedents) and cross-checks figures before relying on them - Strong technical expertise translating clinical and commercial insights into diligence-grade analyses and transaction materials - Ability to structure ambiguous problems and drive them to clear, actionable conclusions in high-stakes settings - Strong financial modeling and valuation skills (risk-adjusted NPV, scenario and sensitivity analysis, capital planning), with the judgment to choose assumptions well and sanity-check outputs against the real world - Familiarity with probabilistic or real options approaches is a plus - Excellent organizational skills and the ability to manage multiple deadlines - Clear and persuasive communicator, both in writing and presentations - Familiarity with industry data platforms like IQVIA and/or financial data platforms like Bloomberg or Capital IQ At BridgeBio, we strive to provide a market-competitive total rewards package, including base pay, an annual performance bonus, company equity, and generous health benefits. Below is the anticipated salary range for candidates for this role who will work in California. The final salary offered to a successful candidate will depend on several factors that may include but are not limited to the type and length of experience within the job, type, and length of experience within the industry, educational background, location of residence and performance during the interview process. BridgeBio is a multi-state employer, and this salary range may not reflect positions based in other states. Salary $237,000—$274,800 USD As a global company, our comprehensive benefits may vary based on location.  We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return. For BridgeBio Full-Time U.S Based Roles: Financial & Rewards - Market-leading compensation - 401(k) with employer match - Employee Stock Purchase Program (ESPP) - Pre-tax commuter benefits (transit and parking) - Referral bonus for hired candidates - Subsidized lunch and parking on in-office days Health & Well-Being - 100% employer-paid medical, dental, and vision premiums for you and your dependents - Health Savings Account (HSA) with annual employer contributions, plus Flexible Spending Accounts (FSA) - Fertility & family-forming benefits - Expanded mental health support (therapy and coaching resources) - Hybrid work model with flexibility - Flexible, “take-what-you-need” paid time off and company-paid holidays - Comprehensive paid medical and parental leave to care for yourself and your family Skill Development & Career Paths: - People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility - We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, & BetterUp Coaching - We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities By applying, you acknowledge that BridgeBio will process your personal information as described in our [Global Candidate Privacy Notice](https://bridgebio.com/bridgebio-global-candidate-privacy-notice). ## About BridgeBio Pharma ## Company Overview - **One-liner**: BridgeBio Pharma develops transformative medicines for genetic conditions, using a decentralized hub-and-spoke model to accelerate drug development from early research to commercialization. - **Entity Type**: Public (Nasdaq: BBIO) - **Headquarters**: Palo Alto, California, USA (with hybrid offices in San Francisco, CA) - **Founded**: Not explicitly stated in provided sources; the company references “over the past 10 years” as of 2026, suggesting founding around 2015–2016. - **Founders**: Not publicly available from provided sources. ## Core Business - **Primary industry**: Biotechnology / Genetic disease therapeutics - **Target customers**: Patients living with genetic conditions, healthcare providers, payers, and academic research partners - **Mission**: “To develop transformative medicines for genetic conditions” and “bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.” ## Products & Services BridgeBio’s pipeline includes both approved therapies and investigational candidates across dozens of indications. Key offerings: - **Acoramidis**: Approved for transthyretin amyloidosis (ATTR) – a first-in-class treatment with $8B+ peak year sales potential. - **Infigratinib**: Phase 3 completed for achondroplasia; published in the *New England Journal of Medicine* (2026). - **BBP-418**: Investigational for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). - **Encaleret**: Investigational for Autosomal Dominant Hypocalcemia Type 1 (ADH1). - **BBP-812**: Investigational for Canavan Disease. - **BridgeBio Oncology Therapeutics (BBOT)**: Subsidiary focused on RAS and PI3Kα-driven cancers. - **GondolaBio**: Subsidiary developing bioavailable small molecule inhibitors for oncology. - **Other programs**: Covering hypochondroplasia, chronic hypoparathyroidism, and more. The company has received **3 FDA approvals** and has over **70+ peer-reviewed publications**. ## Market Standing - **Valuation / Market Cap**: Not explicitly stated in provided data; as a public company, current market cap can be found on financial platforms (e.g., ~$8B based on peak sales potential, but not a direct valuation number). - **Key Metric**: **3 FDA-approved medicines**; **2000+ patients enrolled** in global clinical trials; **6 Phase 3 trials** conducted over the past 10 years. - **Notable Investors / Partners**: Not detailed in provided sources, but the company partners with leading academic institutions to advance early-stage research. - **Growth Signals**: Recent publication of Phase 3 PROPEL 3 trial results in NEJM (June 2026); expansion into oncology via BBOT and GondolaBio; 100% of pipeline is first-in-class or best-in-class; 48 unique disease indications targeted. ## Competitive Advantages - **Hub-and-spoke model**: Decentralized structure where autonomous affiliate teams (spokes) focus on specific conditions, while a central hub provides clinical, regulatory, and commercial expertise. This enables speed, scalability, and risk reduction. - **First-in-class / best-in-class focus**: 100% of pipeline aims to be first or best in class, targeting underserved genetic conditions with clear biological rationale. - **Speed and adaptability**: The model allows rapid pivoting to the most promising opportunities, reducing development timelines compared to traditional biotech. - **Strong scientific foundation**: Over 70 peer-reviewed papers and collaborations with top academic institutions. ## Strategic Focus - **Advance late-stage pipeline**: Prioritize Phase 3 programs (e.g., infigratinib for achondroplasia, acoramidis for ATTR) and seek additional FDA approvals. - **Expand into oncology**: Leverage subsidiaries BBOT and GondolaBio to address RAS/PI3Kα-driven cancers. - **Maintain urgency**: “Every minute counts” – continue to operate with speed and autonomy to bring treatments to patients faster. - **Build on commercial success**: Leverage existing approved products to fund further R&D and expand global reach. ## Why Work Here - **Award-winning culture**: Named **#1 Best Place to Work** by BioSpace (2026, small biotech category) with an **88% employee engagement score** in 2025. - **Flexible work model**: Hybrid policy with offices in San Francisco and Palo Alto, CA; “flexible working model” emphasized. - **Compensation and benefits**: Market-leading pay, comprehensive healthcare, and strong emphasis on growth and internal mobility. - **Impact-driven mission**: Work on transformative treatments for genetic conditions where patient need is urgent – “Impatient for Patients” is a core mantra. - **Values**: Put patients first, let science speak, think independently, speak up, and act with urgency. The culture is described as “high on standards, low on convention.” - **Growth opportunities**: 113 open jobs (as of mid-2026) across functions including clinical, regulatory, manufacturing, commercial, and corporate; talent community available for future roles. ## Sources 1. [bridgebio.com](https://bridgebio.com/) – Home page with pipeline overview and $8B peak sales potential 2. [bridgebio.com/about](https://bridgebio.com/about) – Company description, hub-and-spoke model, and key metrics 3. [bridgebio.com/careers](https://bridgebio.com/careers) – Careers page with awards, culture, and benefits 4. [investor.bridgebio.com](https://investor.bridgebio.com/overview/default.aspx) – Investor relations overview, latest news, and corporate presentation 5. [job-boards.greenhouse.io/bridgebio](http://job-boards.greenhouse.io/bridgebio) – Current job listings (113 roles) and departmental categories ## Other roles at BridgeBio Pharma - [Senior Director, Medical Publications and Scientific Communications](https://feeny.ai/job/senior-director-medical-publications-and-scientific-communications-bridgebio-mn08tjm9zqd1) — United States - [Associate Director, People Operations Leader (Contract)](https://feeny.ai/job/associate-director-people-operations-leader-contract-bridgebio-pharma-san-ek2rdmg8mjwj) — San Francisco, CA - [Associate Director/Director Process Chemistry](https://feeny.ai/job/associate-director-director-process-chemistry-bridgebio-pharma-united-states-13q4kxjthehv) — United States - [Senior Executive Assistant (Field Medical)](https://feeny.ai/job/senior-executive-assistant-field-medical-bridgebio-pharma-united-states-rsyahyk2rb79) — United States - [Therapeutic Sales Specialist - Central (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-central-attruby-bridgebio-pharma-united-states-x9y5xq7hke6a) — United States - [Therapeutic Sales Specialist - Southeast (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-southeast-attruby-bridgebio-pharma-united-states-stspx4mhh6wh) — United States - [Therapeutic Sales Specialist - Great Lakes (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-great-lakes-attruby-bridgebio-pharma-united-states-g99tvebbrwcf) — United States - [Therapeutic Sales Specialist - Mid Atlantic (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-mid-atlantic-attruby-bridgebio-pharma-united-states-20g1x2frxe63) — United States - [Therapeutic Sales Specialist - Northeast (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-northeast-attruby-bridgebio-pharma-united-states-d0h3d71ersq2) — United States - [Therapeutic Sales Specialist - West (Attruby)](https://feeny.ai/job/therapeutic-sales-specialist-west-attruby-bridgebio-pharma-united-states-tfs7wra1ps3j) — United States